Biomarkers of endothelial dysfunction are associated with poor outcome in COVID‐19 patients: A systematic review and meta‐analysis
Reviews in Medical Virology · 2023-07 · 33 (4)
DOI: 10.1002/rmv.2442 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Reviews in Medical Virology, online erschienen am 21.03.2023. Verfasst von Alireza Mohebbi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Blood Banking, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Tissue Plasminogen Activator, COVID-19. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 91 Literaturangaben.
Abstract (Originalsprache)
Numerous studies have linked coronavirus disease 2019 (COVID‐19) with endothelial dysfunction and reported elevated levels of endothelial biomarkers in this disease. We conducted a systematic review and meta‐analysis of the published evidence in this respect. A systematic literature search of PubMed and Scopus databases was performed to find studies investigating biomarkers of endothelial dysfunction in COVID‐19 patients. Pooled standardized mean differences and their 95% confidence intervals were calculated for each biomarker using random effect model. 74 studies with 7668 patients were included. In comparison to patients with good outcome, those with poor outcome had higher levels of von Willebrand factor (vWF) (SMD: 0.83, 95% CI: 0.59–1.07, p < 0.00001), vWF:ADAMTS13 (1.23, (0.77–1.7), p < 0.00001), angiopoietin‐2 (Ang‐2) (1.06 (0.6–1.51), p < 0.0001), E‐selectin (1.09 (0.55–1.63), p < 0.0001), P‐selectin (0.59 (0.24–0.94), p = 0.001), syndecan‐1 (0.99 (0.6–1.37), p < 0.00001), mid‐regional pro‐adrenomedullin (MR‐proADM) (1.52 (1.35–1.68), p < 0.00001), vascular endothelial growth factor (0.27 (0.02–0.53), p = 0.03), soluble fms‐like tyrosine kinase‐1 (sFLT‐1) (1.93 (0.65–3.21), p = 0.03) and lower levels of ADAMTS13 antigen (−0.69 (−0.9 to −0.47) p < 0.00001) and activity (−0.84 (−1.06 to −0.61) p < 0.0000). Plasminogen activator inhibitor‐1 and tissue plasminogen activator levels were not different between the two groups ( p < 0.05). There were elevated levels of endothelial dysfunction biomarkers in COVID‐19 patients with poor outcome, indicating their possible role in disease severity and prognosis. In particular, MR‐proADM, vWF, syndecan‐1 and sFLT‐1 showed a significant association with poor outcome in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Cardiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
- Department of Medical Laboratory, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
ORCID-Profile: Najmaldin Saki
Zitieren
APA
Mohebbi, A., Haybar, H., Nakhaei Moghaddam, F., Rasti, Z., Vahid, M. A., & Saki, N. (2023). Biomarkers of endothelial dysfunction are associated with poor outcome in COVID‐19 patients: A systematic review and meta‐analysis. Reviews in Medical Virology, 33(4). https://doi.org/10.1002/rmv.2442
Vancouver
Mohebbi A, Haybar H, Nakhaei Moghaddam F, Rasti Z, Vahid MA, Saki N. Biomarkers of endothelial dysfunction are associated with poor outcome in COVID‐19 patients: A systematic review and meta‐analysis. Reviews in Medical Virology. 2023;33(4). doi:10.1002/rmv.2442
BibTeX
@article{Mohebbi2023,
author = {Mohebbi, Alireza and Haybar, Habib and Nakhaei Moghaddam, Fatemeh and Rasti, Zahra and Vahid, Mohammad Amin and Saki, Najmaldin},
title = {Biomarkers of endothelial dysfunction are associated with poor outcome in COVID‐19 patients: A systematic review and meta‐analysis},
journal = {Reviews in Medical Virology},
year = {2023},
volume = {33},
number = {4},
doi = {10.1002/rmv.2442}
}
EUVIMED